



Novel Immunotherapies for Solid Tumors: Present and Future

**THURSDAY,
JULY 3**

**AUDITORI, HOSPITAL
UNIVERSITARI DEXEUS
C/SABINO DE ARANA 5-19, BARCELONA**

CHECK THE FULL PROGRAM →

ORGANIZERS

Dr. González-Cao & Dr. Rafael Rosell
Institut Oncològic Dr. Rosell, Hospital Universitari Dexeus, Barcelona

Fundación IOR
Email: mgonzalezcao@oncorosell.com

REGISTRATION REQUIRED

Please send an email with your name and affiliation to Stephanie Davis (sdavis@oncorosell.com).

Registrations will be processed on a first-come, first-served basis until capacity is reached. If you are registered but unable to attend, please notify us in advance. If you will only attend part of the program, include the specific hours of attendance in your email.

SPONSORS: IMMUNOCORE **REGENERON**



IOVANCE
BIOTHERAPEUTICS

PROGRAM

8:20 AM	WELCOME
	Dr. Rosell & Dr. Gonzalez-Cao
8:30 AM	INTRODUCTION TALK: The Oncologist's Point of View in Immunotherapy
9:00 AM	Dr. Rosell (Institut Oncològic Dr. Rosell, Hospital Universitari Dexeus, Barcelona)
9:00 AM	SESSION I: T Cell Therapy in Solid Tumors
11:00 AM	Chairperson: Inge Mansfield Noringriis, MD (National Center for Cancer Immune Therapy - CCIT-DK, Department of Oncology, Herlev Hospital, Copenhagen)
	9:00 AM - 9:20 AM Lifileucel and Next-Generation TIL Products Ewelina Testoni, PhD (Field Medical Advisor ex-USA, IOVANCE BIOTHERAPEUTICS)
	9:30 AM - 9:50 AM Predictors of Response to TIL Therapy Joachim Stoltenborg Granhøj, MD (National Center for Cancer Immune Therapy - CCIT-DK, Department of Oncology, Herlev Hospital, Copenhagen)
	10:00 AM - 10:20 AM ACTengine® IMA203 TCR-T Targeting PRAME in PD1 Refractory Metastatic Melanoma Cedrik Britten, MD (Chief Medical Officer, IMMATICS, Germany)
10:30 AM - 11:00 AM Coffee Break	
11:00 AM	SESSION II: Enhancing Antigen Presentation for Cancer Treatment
1:00 PM	Chairperson: Marta Sistere, PhD (Infection Biology Laboratory, MELIS, Universitat Pompeu Fabra, Barcelona)
	11:00 AM - 11:20 AM XCR1+ DCs are Critical for T Cell-Mediated Immunotherapy Andreas Meyerhans, PhD (ICREA & Universitat Pompeu Fabra, Barcelona)
	11:30 AM - 11:50 AM How to Improve the Activity of Dendritic Cell Vaccines in Cancer Daniel Benitez, PhD (Immunology Department, Hospital Clínic, Barcelona)
	12:00 PM - 12:20 PM Extrachromosomal DNA: A Source for mRNA Vaccines in Cancer Jonas Nilson, PhD (University of UMEA, Sweden)
	12:30 PM - 12:50 PM Using Topical Immunomodulators and Laser Therapy for Enhancing Anti-Tumoral Response: CEMIQUID Trial Susana Puig, MD (Dermatology Department, Hospital Clínic, Barcelona)

PROGRAM

1:00 PM – 1:45 PM | Lunch

2:00 PM	SESSION III: Private and Public Neoantigens
3:30 PM	Chairperson: Alejandro Martinez Bueno, MD (Institut Oncològic Dr. Rosell, Hospital Universitari Dexeus, Barcelona)
	2:00 PM – 2:20 PM Methods for Neoantigen Identification: Understanding Their Accuracy Nuria de la Iglesia, PhD (IrsiCaixa AIDS Research Institute, Barcelona)
	2:30 PM – 2:50 PM Identification of Personalized Neoantigen Reactive TCRs from TIL Alena Gros, PhD (Vall de Hebron, Barcelona, Spain)
	3:00 PM – 3:20 PM Targeting Public Neoantigens for Cancer Immunotherapy Julia Blanco, PhD (IrsiCaixa AIDS Research Institute, Barcelona)
3:30 PM	SESSION IV: T Cell Engagers Using TCRs to Target Tumor Cells
5:00 PM	Chairperson: Rafael Rosell, MD, PhD (Institut Oncològic Dr. Rosell, Hospital Universitari Dexeus, Barcelona)
	3:30 PM – 3:50 PM Generation of ImmTAC Molecules Sarah Stanhope, (Immunocore, Abingdon, UK)
	4:00 PM – 4:20 PM Tebentafusp: First ImmTAC Approved JM Piulats, MD (Oncology Department, Hospital de Bellvitge, Barcelona)
	4:30 – 4:50 PM Other T Cell Engagers in Solid Tumors Enriqueta Felip, MD, PhD (Hospital Vall de Hebron, Barcelona)
5:00 PM	SESSION V: Practical Aspects for Clinical Development of Novel Immunotherapies
6:00 PM	Chairperson: Irene Moya, MD, PhD (Institut Oncològic Dr. Rosell, Hospital Universitari Dexeus, Barcelona)
	5:00 PM – 5:20 PM Integrating Spatial Technologies for the Interrogation of Cancer Evolution in the Tumor Immune Microenvironment MA Molina, PhD (Institut Oncològic Dr. Rosell, Hospital Universitari Dexeus, Barcelona)
	5:30 PM – 5:50 PM Key Logistical Challenges in Cell Therapy Clinical Trials Carlos Esparre, PhD (Institut Oncològic Dr. Rosell, Hospital Universitari Dexeus, Barcelona)
6:00 PM	CLOSING REMARKS
6:10 PM	María González-Cao, MD (Institut Oncològic Dr. Rosell, Hospital Universitari Dexeus, Barcelona)

Fundación  **IOR**